Minerva Neurosciences (NASDAQ:NERV) Issues Quarterly Earnings Results

Minerva Neurosciences (NASDAQ:NERV) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.49, Zacks reports.

Minerva Neurosciences Price Performance

NASDAQ NERV traded down $0.03 on Friday, hitting $1.68. 5,798 shares of the company’s stock were exchanged, compared to its average volume of 46,747. The firm has a market cap of $11.71 million, a price-to-earnings ratio of -3.81 and a beta of 0.12. The firm’s 50-day moving average price is $2.15 and its two-hundred day moving average price is $2.39. Minerva Neurosciences has a fifty-two week low of $1.64 and a fifty-two week high of $3.69.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on NERV shares. StockNews.com assumed coverage on Minerva Neurosciences in a report on Saturday, February 22nd. They set a “sell” rating for the company. HC Wainwright restated a “neutral” rating and set a $5.00 price objective on shares of Minerva Neurosciences in a research report on Wednesday.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.